Larimar Therapeutics has made notable progress regarding its regulatory milestones for nomlabofusp, its lead treatment candidate for Friedreich's ataxia. The company reported positive open-label study data demonstrating a well-characterized safety profile and sustained increases in skin frataxin levels. Furthermore, Larimar initiated a rolling Biologics License Application (BLA) seeking accelerated approval from the FDA, backed by an upsized public offering that successfully strengthened its balance sheet with substantial cash reserves to fund ongoing clinical developments.